IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia

Affiliations

• ¹ Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
• ² Department of Pathology, Institut Universitaire du Cancer, CHU de Toulouse, Toulouse, France.
• ³ Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
• ⁴ Hospital Clínic of Barcelona, Barcelona, Spain.
• ⁵ Biología Molecular e Histocompatibilidad, Instituto de Investigación Biomédica de Salamanca-Hospital Universitario, Centro de Investigación del Cáncer-Instituto de Biología Molecular y Celular del Cáncer, University of Salamanca-Spanish National Research Council, Salamanca, Spain.
• ⁶ Servicio de Hematología y Hemoterapia, Hospital Universitario Central de Asturias, Oviedo, Spain.
• ⁷ Servicio de Hematología, Hospital Clínico Universitario, Instituto de Investigación Sanitaria (INCLIVA), Universidad de Valencia, Valencia, Spain.
• ⁸ European Molecular Biology Laboratory, Heidelberg, Germany.
• ⁹ The Broad Institute of MIT and Harvard, Cambridge, MA.
• ¹⁰ The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel.
• ¹¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
• ¹² Harvard Medical School, Boston, MA.
• ¹³ Department of Medicine, Brigham and Women's Hospital, Boston, MA.
• ¹⁴ Center for Cancer Research, Massachusetts General Hospital, Boston, MA.
• ¹⁵ Department of Pathology, Massachusetts General Hospital, Boston, MA.
• ¹⁶ Department of Medical Oncology and Hematology, University Hospital and University of Zürich, Zurich, Switzerland.
• ¹⁷ Universitat de Barcelona, Barcelona, Spain.
• ¹⁸ Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.